Skip to main content
SpringerLink
Log in

GED-0507 is a novel potential antifibrotic treatment option for pulmonary fibrosis

  • Correspondence
  • Published:
Cellular & Molecular Immunology Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1: Study design and main findings following preventive and curative administration of GED-0507.

References

  1. Raghu, G. et al. Incidence and prevalence of idiopathic pulmonary fibrosis in US adults 18–64 years old. Eur. Respir. J. 48, 179–186 (2016).

    Article  Google Scholar 

  2. Raghu, G. et al. An Official ATS/ERS/JRS/ALAT Clinical Practice Guidelines: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline. Am. J. Respir. Crit. Care Med. 192, e3–e19 (2015).

    Article  Google Scholar 

  3. Skandamis, A. et al. Systematic review and network meta-analysis of approved medicines for the treatment of idiopathic pulmonary fibrosis. J. Drug Assess. 8, 55–61 (2019).

    Article  Google Scholar 

  4. Speca S. et al. Novel PPARγ modulator GED-0507-34 levo ameliorates inflammation-driven intestinal fibrosis. Inflamm. Bowel Dis. 22, 279–292 (2016).

  5. Spagnolo, P. & Cottin, V. Genetics of idiopathic pulmonary fibrosis: from mechanistic pathways to personalised medicine. J. Med. Genet. 54, 93–99 (2017).

    Article  Google Scholar 

  6. Pirat, C. et al. Targeting peroxisome proliferator-activated receptors (PPARs): development of modulators. J. Med. Chem. 55, 4027–4061 (2012).

    Article  CAS  Google Scholar 

  7. Fumery, M. et al. Peroxisome proliferator-activated receptor gamma (PPARγ) regulates lactase expression and activity in the gut. EMBO Mol. Med. 9, 1471–1481 (2017).

    Article  CAS  Google Scholar 

  8. Rousseaux, C. et al. Preclinical evaluation of intestinal anti-inflammatory/analgesic properties and phase I clinical trial of a new PPAR Agonist Ged-0507-34-Levo. Gastroenterology 140, S-515 (2011).

  9. Di Gregorio, J. et al. Role of glycogen synthase kinase-3β and PPAR-γ on epithelial-to-mesenchymal transition in DSS-induced colorectal fibrosis. PLoS ONE 12, e0171093 (2017).

    Article  Google Scholar 

  10. Ashcroft, T. et al. Simple method of estimating severity of pulmonary fibrosis on a numerical scale. J. Clin. Pathol. 41, 467–470 (1988).

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We thank Nogra Pharma Ltd., Dublin, Ireland, for partly funding this study. Nogra Pharma Ltd. has filed a patent for the use of GED-0507 in inflammatory/fibrotic diseases.

Author information

Authors and Affiliations

  1. The University of Lille, INSERM, U1286 – Infinite – Institute for Translational Research in Inflammation, Lille, France

    Silvia Speca, Philippe Chavatte & Pierre Desreumaux

  2. Intestinal Biotech Development, Lille, France

    Caroline Dubuquoy & Christel Rousseaux

  3. Laboratoire de Pharmacie Clinique, Faculté des Sciences Pharmaceutiques et Biologiques, Lille, France

    Philippe Chavatte

  4. CHU Lille, Hepato-Gastroenterology Department, Lille, France

    Pierre Desreumaux

  5. Respiratory Disease Unit, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova, Padova, Italy

    Paolo Spagnolo

Authors
  1. Silvia Speca
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Caroline Dubuquoy
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Christel Rousseaux
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Philippe Chavatte
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Pierre Desreumaux
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Paolo Spagnolo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Paolo Spagnolo.

Ethics declarations

Competing interests

P.D. reports personal fees from PPM Services, during the conduct of the study; personal fees from Ferring, Switzerland; personal fees from Intralytix, USA; personal fees from Lesaffre, France; personal fees from KitoZyme, Belgium; personal fees from Abbott, France; personal fees from Janssen, France; personal fees from MSD, France; personal fees from Norgine, France; personal fees from Pfizer, France; personal fees from Takeda, France, outside the submitted work. P.S. reports personal fees from PPM Services during the conduct of the study; grants, personal fees and non-financial support from Roche; grants and non-financial support from PPM Services; grants, personal fees and non-financial support from Boehringer-Ingelheim; personal fees from RedX Pharma; personal fees from Galapagos; personal fees from Chiesi, outside the submitted work. S.S., C.D., C.R., and P.C. have nothing to disclose.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Speca, S., Dubuquoy, C., Rousseaux, C. et al. GED-0507 is a novel potential antifibrotic treatment option for pulmonary fibrosis. Cell Mol Immunol 17, 1272–1274 (2020). https://doi.org/10.1038/s41423-020-0394-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41423-020-0394-y

  • Springer Nature Limited

Search

Navigation